pentetic acid has been researched along with lutetium lu 177 dotatate in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakker, WH; Breeman, WA; De Jong, M; Jamar, F; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Pauwels, S; Smith, C; Valkema, R | 1 |
| Bernard, BF; Breeman, WA; de Jong, M; Erion, JL; Krenning, EP; van der Wansem, K; van Gameren, A; Visser, TJ | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Johanson, V; Kölby, L; Nilsson, O | 1 |
| Anthony, LB; Bodei, L; Chinol, M; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Maecke, HR; Mueller-Brand, J; O'dorisio, TM; Paganelli, G; Pauwels, S; Valkema, R | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Kölby, L; Nilsson, O; Schmitt, A | 1 |
| de Jong, M; Esser, JP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R | 1 |
| Berndsen, SC; Boerman, OC; de Jong, M; de Swart, J; de Visser, M; Koelewijn, S; Krenning, EP; Melis, M; Valkema, R | 1 |
| Bulzico, DA; Carneiro, M; Corbo, R; de Carvalho Leal, D; Kendler, DB; Lopes, FP; Pessoa, CH; Rosado de Castro, PH; Vaisman, F; Vaisman, M; Vilhena, B | 1 |
3 review(s) available for pentetic acid and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
Topics: Animals; Humans; Indium Radioisotopes; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Tumor Cells, Cultured; Yttrium Radioisotopes | 2002 |
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Humans; Neoplasms; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Pentetic Acid; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiation Injuries; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Treatment Outcome | 2005 |
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Patient Selection; Pentetic Acid; Peptides, Cyclic; Quality of Life; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes | 2005 |
1 trial(s) available for pentetic acid and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Octreotide; Organometallic Compounds; Pentetic Acid; Quality of Life; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed | 2015 |
4 other study(ies) available for pentetic acid and lutetium lu 177 dotatate
| Article | Year |
|---|---|
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Topics: Animals; Bone Marrow; Femur; Heterocyclic Compounds, 1-Ring; Injections, Intravenous; Kidney; Lutetium; Male; Octreotide; Organ Specificity; Organometallic Compounds; Pentetic Acid; Radiation-Protective Agents; Radioisotopes; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution | 2003 |
GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors.
Topics: Animals; Carcinoid Tumor; Disease Models, Animal; Indium Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Xenograft Model Antitumor Assays | 2004 |
Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Topics: Animals; Carcinoma, Small Cell; Cell Line, Tumor; Disease Models, Animal; Humans; Indium Radioisotopes; Liver; Lung; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Octreotide; Organometallic Compounds; Organotechnetium Compounds; Pentetic Acid; Radiopharmaceuticals; Somatostatin; Time Factors; Tissue Distribution | 2005 |
Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
Topics: Albumins; Animals; Autoradiography; Creatinine; Glomerular Filtration Rate; Kidney; Kidney Diseases; Kidney Tubules; Lysine; Male; Octreotide; Organometallic Compounds; Pentetic Acid; Proteinuria; Radiation Injuries; Radioisotope Renography; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Technetium Tc 99m Dimercaptosuccinic Acid; Technetium Tc 99m Mertiatide; Tomography, Emission-Computed, Single-Photon | 2010 |